Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06634394 · ClinicalTrials.gov registry record · Phase 1
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
A Phase 1 study of Acute Myeloid Leukemia (AML), sponsored by Aptevo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 7
- Study locations
NCT06634394 is a Phase 1 study of Acute Myeloid Leukemia (AML) that is actively recruiting participants, run by Aptevo Therapeutics. The registered enrollment target is 39 participants, below the 144-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT06634394, a Phase 1 study of Acute Myeloid Leukemia (AML), is actively recruiting participants, sponsored by Aptevo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 7
- Study locations
Study Summary
A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG APVO436
Study Locations (7)
Ohio
- Gabrail Cancer Center - Canton
- Oncology Hematology Care - Cincinnati
Texas
- University of Texas Southwestern Medical Center - Dallas
- MD Anderson Cancer Center - Houston
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- University of Miami - Miami
Kansas
- University of Kansas - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06634394
The ClinicalTrials.gov registry entry for NCT06634394 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (73% lower). The listed sponsor is Aptevo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT06634394 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Ohio, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT06634394 about?
NCT06634394 is a clinical study titled "APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML". A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
What is the current status of trial NCT06634394?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2024-10-01. Estimated completion is 2028-03.
What conditions does trial NCT06634394 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT06634394?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), APVO436 (DRUG).
Who is sponsoring clinical trial NCT06634394?
This trial is sponsored by Aptevo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06634394 being conducted?
This trial has 7 study locations across Colorado, Florida, Kansas, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
RECRUITING · Phase 1
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
-
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
RECRUITING · Phase 1
-
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.